Acute kidney injury and long-term renal effects of alectinib in anaplastic lymphoma kinase-positive non-small cell lung carcinoma: a case report
Abstract Background Targeted therapy with anaplastic lymphoma kinase inhibitor alectinib has become standard therapy for selected patients with non-small cell lung carcinoma. Few data are available on the renal effects of alectinib. We report on a case of acute kidney injury in a patient using alect...
Main Authors: | Marco van Londen, Elizabeth Roosma, Stefanie Vogels, John W. G. van Putten, Wilbert M. T. Janssen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-09-01
|
Series: | Journal of Medical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13256-022-03532-2 |
Similar Items
-
The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China
by: Zhanjing Dai, et al.
Published: (2024-04-01) -
ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature
by: Nobuaki Mamesaya, et al.
Published: (2017-07-01) -
Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib
by: Cass G. G. Sunga, et al.
Published: (2023-03-01) -
High incidence and reversible bradycardia events following alectinib initiation
by: Dongqi Yuan, et al.
Published: (2023-02-01) -
Acquired L1196M ALK mutation in anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma during alectinib administration
by: Kazuhiro Noguchi, et al.
Published: (2023-02-01)